A comprehensive view of Diabetes. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Bioeconomy Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

High demand for injectable weight-loss drugs has led to supply issues, with most varieties listed in short supply by the FDA; Eli Lilly reports shortages of its Zepbound and Mounjaro could last until 2025
Published: April 19, 2024 by CBS - 12 WJTV (Jackson, MS)
Nestle SA Gets Patent for Compositions Comprising Citrulline and Leucine and Their Use in the Treatment of Diabetes and Metabolic Syndrome
Published: April 18, 2024 by Pharmaceutical Patent News
Eli Lilly and plaintiffs abandon proposed US$13.5M settlement regarding alleged overpricing of insulin; the move follows a court ruling against certifying specific state-classes in the case
Published: April 17, 2024 by FiercePharma
INTERNATIONAL PATENT: ELI LILLY AND COMPANY FILES APPLICATION FOR "PEPTIDES FOR INCRETIN SYNTHESIS"
Published: April 17, 2024 by U.S. Fed News
GlobalData predicts GLP-1 drugs will redefine big pharma sales; Eli Lilly's diabetes drug, Mounjaro, is forecasted to generate US$34.0B by 2029, surpassing the entire 2023 portfolio of Lilly, with the Alzheimer's drug donanemab adding another US$5.0B
Published: April 17, 2024 by FiercePharma

Ask us about our Bioeconomy market view

Trending Chart

Interactive chart with headline count